Spruce Biosciences Inc logo

SPRB

Spruce Biosciences Inc

$2.03

Earnings Summary

Revenue
$0Mn
Net Profits
$-11.76Mn
Net Profit Margins
-Inf%

Highlights

Revenue:

Spruce Biosciences Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Spruce Biosciences Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Spruce Biosciences Inc’s net profit fell -18.96% since last year same period to $-11.76Mn in the Q1 2022. On a quarterly growth basis, Spruce Biosciences Inc has generated -28.07% fall in its net profits since last 3-months.

Net Profit Margins:

Spruce Biosciences Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Spruce Biosciences Inc has generated NaN% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Spruce Biosciences Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.52
EPS Estimate Current Year
-0.52

Highlights

EPS Estimate Current Quarter:

Spruce Biosciences Inc’s earning per share (EPS) estimates for the current quarter stand at -0.52 - a -13.04% fall from last quarter’s estimates.

EPS Estimate Current Year:

Spruce Biosciences Inc’s earning per share (EPS) estimates for the current year stand at -0.52.

Key Ratios

Key ratios of the Spruce Biosciences Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.5
Return on Assets (ROA)
-0.22
Return on Equity (ROE)
-0.4
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Spruce Biosciences Inc’s earning per share (EPS) fell -19.05% since last year same period to -0.5 in the Q1 2022. This indicates that the Spruce Biosciences Inc has generated -19.05% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Spruce Biosciences Inc’s return on assets (ROA) stands at -0.22.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Spruce Biosciences Inc’s return on equity (ROE) stands at -0.4.

Dividend Per Share (DPS):

Spruce Biosciences Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-11
-0.46
-0.5
-8.7%

Company Information

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years. Spruce is also developing tildacerfont for women suffering from a rare form of polycystic ovary syndrome (PCOS) with primary adrenal androgen excess, representing 3-5% of females with PCOS (estimated to be 150,000 to 200,000 patients in the United States).

Organisation
Spruce Biosciences Inc
Employees
17
Industry
Commercial Services